Cargando…
BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I
The activation of the transcription factor hypoxia-inducible factor-1 (HIF-1) plays an essential role in tumor development, tumor progression, and resistance to chemo- and radiotherapy. In order to identify compounds targeting the HIF pathway, a small molecule library was screened using a luciferase...
Autores principales: | Ellinghaus, Peter, Heisler, Iring, Unterschemmann, Kerstin, Haerter, Michael, Beck, Hartmut, Greschat, Susanne, Ehrmann, Alexander, Summer, Holger, Flamme, Ingo, Oehme, Felix, Thierauch, Karlheinz, Michels, Martin, Hess-Stumpp, Holger, Ziegelbauer, Karl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Science Inc
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892793/ https://www.ncbi.nlm.nih.gov/pubmed/24403227 http://dx.doi.org/10.1002/cam4.112 |
Ejemplares similares
-
BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts
por: Helbig, Linda, et al.
Publicado: (2014) -
Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth
por: Schöckel, Laura, et al.
Publicado: (2015) -
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876
por: Siebeneicher, Holger, et al.
Publicado: (2016) -
Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects
por: Flamme, Ingo, et al.
Publicado: (2014) -
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)